Abstract
Lipopolysaccharide (LPS) is located on the cell wall of gram-negative bacteria and plays an important role in the pathogenesis of sepsis, which continues to be a leading cause of death in the intensive care units. There are many strains and serotypes of gram-negative bacteria and each individual has a unique kind of LPS. In addition, LPS belongs to thymus-independent (TI) antigen, making it difficult to produce high-affinity, cross-reactive monoclonal antibodies (MAb) against LPS. Here we report a novel method to produce cross-reactive murine MAbs against LPS by mixed immunization with whole cell bacteria, commercial LPS, and synthetic peptide, which simulates the structure of LPS. Using this approach, an MAb designated SMU-3A8 was generated, which can react with four commercial LPSs and seven gram-negative bacteria with high affinity suited for ELISA, dot-ELISA, Western blotting, immunofluorescence, and flow cytometry. Our results provide a new strategy for the generation of high-affinity, cross-reactive MAbs against LPS and other TI antigens.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
